First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity signals of MSC2363318A.
Solid Tumor
DRUG: MSC2363318A|DRUG: MSC2363318A plus Trastuzumab|DRUG: MSC2363318A plus Tamoxifen
Number of dose limiting toxicities (DLTs) in Dose Escalation and Trastuzumab or Tamoxifen combination arms, Up to Day 21 of Cycle 1|Number of subjects with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs), and deaths in cohort for subjects with PAM pathway alterations, Baseline up to Day 30 after the last dose of study treatment
Observed Maximum Plasma Concentration (Cmax), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Time To Reach Maximum Plasma Concentration (Tmax), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Area Under Plasma Concentration Versus Time Curve From Time Zero to Last Sampling Time (AUC0-t), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Apparent Terminal Half-life ( t1/2), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Apparent Oral Clearance (CL/F), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Apparent Oral Clearance Steady State (CLss/F), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Apparent Volume of Distribution (Vz/F), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Apparent Volume of Distribution at Steady State (Vss/F), Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Factor to Assess the Increase of Drug Concentration in Plasma Until Steady State is Reached [Racc(AUC)], Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Factor to Assess the Maximal Increase of Drug Concentration in Plasma [Racc (Cmax)], Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2, Cycle 3|Number of subjects with best overall response according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) or Cheson 2007, Evaluation were performed on Day 1 of every alternate cycle until tumor progression|Percentage of subjects with clinical benefit, Percentage of subjects with clinical benefit is defined as subjects with complete response (CR) or partial response (PR) at week 12, based on tumor assessment as determined by RECIST version 1.1 or Cheson 2007., Week 12|Disease control rate (DCR) for Cohort 2 only, Week 6|Progression-free survival (PFS) rate for Cohorts 2 and 3 only, up to 6 months
This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity signals of MSC2363318A.